Figure 2 - uploaded by Christo Damyanov
Content may be subject to copyright.
Bi-Digital O-Ring test Dr. Omura is a general practitioner and cardiologist with more than 50 years long outstanding practice. He is the president and founder of International College of Acupuncture & Electro Therapeutics and international medical association International Bi-Digital O-Ring Test Medical Association and also Director of Heart Disease Research Foundation. After 1993 he has published a lot of articles focused on the diagnostics and treatment of cancer diseases.(15)
Context in source publication
Context 1
... AMT The information is taken from: Bi-Digital O-Ring Test (BDORT) The Bi-Digital O-Ring Test is applicable for the following topics: drugs selection and dosage, assessment of sensitivity to foods and food supplements, evaluation electromagnetic field impact, acupuncture points location, and energetic meridians location. (18,19,20,21,22,23) www.worldwidejournals.com ...
Similar publications
Os tratamentos em oncologia têm vindo a aumentar, tanto em número como em complexidade. A existência de um acesso vascular central seguro e adequado à terapêutica a realizar é fundamental, promovendo a melhor prática no cuidado ao doente com cancro.O cateter venoso central totalmente implantado permite a administração segura de terapêuticas antineo...
Citations
... Entering into new era, we should promote acupuncture study and clinical application in a systematic way. Treatment schedules and protocols (temperature, treatment duration, electric-supportive and others) need to be customized [19][20][21] and cooperative ways (personalized medicine) [22][23][24][25][26]. ...
Acupuncture is widely used for bone disease treatments in China. However, it needs to cope with modern medicine. This editorial provides new acupuncture approaches in modern medicine.
... Treatment schedules and protocols (temperature, treatment duration, electric-supportive and others) need to be customized [19][20][21] and cooperative ways (personalized medicine) [22][23][24][25][26]. ...
Acupuncture is widely used for bone disease treatments in China. However, it needs to cope with modern medicine. This editorial provides new acupuncture approaches in modern medicine.
... The recorded information discs are placed on the receiver of SWG-A towers, and a bottle of water for homeopathic transfer is placed on the transmitter. The procedure lasts 30 minutes with correction of the magnetic imbalance, and the result is controlled by an autonomous muscle test (49). The scalar information transfer of biomagnetic therapy is not inferior to the effectiveness of static magnet therapy, and has the advantage of accessibility and reduced duration of the treatment procedure. ...
... The duration of the procedure is 30 minutes and is performed once a week. We perform an autonomous muscle test (also called neuromodulation test) at each procedure to assess the effectiveness and the individual duration of treatment (49). The effectiveness of the treatment is also monitored with standard tests used in oncology. ...
... The recorded information discs are placed on the receiver of SWG-A towers, and a bottle of water for homeopathic transfer is placed on the transmitter. The procedure lasts 30 minutes with correction of the magnetic imbalance, and the result is controlled by an autonomous muscle test (49). The scalar information transfer of biomagnetic therapy is not inferior to the effectiveness of static magnet therapy, and has the advantage of accessibility and reduced duration of the treatment procedure. ...
... The duration of the procedure is 30 minutes and is performed once a week. We perform an autonomous muscle test (also called neuromodulation test) at each procedure to assess the effectiveness and the individual duration of treatment (49). The effectiveness of the treatment is also monitored with standard tests used in oncology. ...
... The opportunities given by АМТ are of prior consideration when we define the chemosensitivity of cytostatic agents in use with IPT. The above mentioned advantages of the test made ATM a leading method in our decision making process in cancer patients' treatment [9]. ...
... In order to select the medicaments and supplements prior to and during the treatment we used modification of Prof. Omura muscle testing [15]. ...
... The experience acquired so far by us in applying the two diagnostic methods indicated a similar performance in 80% to 90 % of the cases. Thus using both diagnostic tests allows us to prepare individualised therapeutic programmes for the patients treated to the clinic [15]. ...
... The opportunities given by АМТ are of prior consideration when we define the chemosensitivity of cytostatic agents in use with IPT. The above mentioned advantages of the test made ATM a leading method in our decision making process in cancer patients' treatment [9]. ...
The current presentation displays chronologically our summarized and updated results of more than 12 years of the accumulated experience of integrative oncology application in our medical practice. Based on our concept of systemic approach, we have created treatment protocol for cancer patients with leading method of administering Insulin Potentiation Therapy (IPT). For the past 12 years period we treated more than 1100 cancer patients, greater part of which (94%) were patients with advanced metastatic tumors (Т2-Т4) and more than 80% of them experienced failure of previous conventional treatment for cancer with chemo-and radiotherapy. The achieved treatment results demonstrated remission in about 80% of the patients, and were presented in our earlier publications. In search for new opportunities of improvement of our treatment efficiency since April 2018, we created treatment method which includes combination of IPT with Biomagnetic therapy with magnetic pairs. (IPT & BMP). Until August 2019 this specific treatment has been applied to 33 cancer patients with advanced metastatic tumors (Т2-Т4) in which 19 out of 23 (82%) experienced failure of previous standard treatment. Twenty-three patients have completed their treatment and were followed up by us. Out of them, 5 patients (21%) have achieved complete remission, and 17 patients (74%) have achieved stabilization. The average remission period is 10 months up till now. Registered failed treatment is present in only one case. Illustrating the opportunities of the new method, we present herewith two new cases with the results of complete clinical remission. In our opinion, the results are an illustration of the opportunities of the Integrative oncology, and the need for change in the concept for cancer patients' treatment.
Aims
Cancer is a high-mortality disease (9.6 million deaths in 2018 worldwide). Given various anticancer drugs, drug selection plays a key role in patient survival in clinical trials.
Methods
Drug Sensitivity Testing (DST), one of the leading drug selective systems, was widely practiced for therapeutic promotion in the clinic. Notably, DSTs assist in drug selection that benefits drug responses against cancer from 20-22% to 30-35% over the past two decades. The relationship between drug resistance in vitro and drug treatment benefits was associated with different tumor origins and subtypes. Medical theory and underlying DST mechanisms remain poorly understood until now. The study of the clinical scenario, sustainability and financial support for mechanism and technical promotions is indispensable
Results
Despite the great technical advance, therapeutic prediction and drug selection by DST needs to be miniature, versatility and cost-effective in the clinic. Multi-parameters and automation of DST should be a future trend. Advanced biomedical knowledge and clinical approaches to translating oncologic profiles into drug selection were the main focuses of DST developments. With a great technical stride, the clinical architecture of the DST platform was entering higher levels (drug response testing at any stage of cancer patients and miniaturization of tumor samples).
Discuss
The cancer biology and pharmacology for drug selection mutually benefit the clinic. New proposals to reveal more therapeutic information and drug response prediction at genetic, molecular and omics levels should be estimated overall.
Conclusion
By upholding this goal of non-invasive, versatility and automation, DST could save the life of several thousand annually worldwide. In this article, new insights into DST novelty and development are highlighted.
The techniques and qualities of drug sensitivity testing (DST) for anticancer treatment grew rapidly in the past two decades worldwide. Much of DST progress came from advanced systems of technical versatility (faster, high-throughput, high-sensitive and smaller in tumor quantity). As the earliest drug selective system, biomedical knowledge and technical advances for DST are mutually supported. More importantly, many pharmacological controversies are resolved by these technical advances. With this technical stride, clinical landscape of DST was entering into a new phase (>500 samples per testing and extremely low quantity of tumor cells). As a forerunner of drug selection system, DST awaits new version that can adapt to complicated therapeutic situations and diverse tumor categories in the clinic. By upholding this goal of pathogenic and therapeutic diversity, DST could eventually cure more cancer patients by establishing high-quality drug selection systems. To smooth DST develop, it needs to increasingly understanding of cancer biology, pathology and pharmacology (cancer heterogeneity, plasticity, metastasis and drug resistance) with well-informative parameters before chemotherapy. In this Article, medicinal and technical insights into DST are especially highlighted.
